tiprankstipranks
Trending News
More News >
Flora Growth (FLGC)
NASDAQ:FLGC
US Market

Flora Growth (FLGC) AI Stock Analysis

Compare
282 Followers

Top Page

FL

Flora Growth

(NASDAQ:FLGC)

Rating:42Neutral
Price Target:
$0.50
▼(-24.24%Downside)
The overall stock score reflects significant financial instability as the primary factor, with persistent losses and a weakened balance sheet posing substantial risks. Technical analysis provides some short-term positive signals, but the overall valuation remains unattractive due to continued negative earnings. Strategic changes are essential for improving financial health and long-term prospects.

Flora Growth (FLGC) vs. SPDR S&P 500 ETF (SPY)

Flora Growth Business Overview & Revenue Model

Company DescriptionFlora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products to pharmacies, medical clinics, and cosmetic companies worldwide. It cultivates, processes, and supplies medicinal-grade cannabis oil, and cannabis derived medical and wellness products; offers skincare and beauty products; develops plant-based and medical-grade pharmaceuticals, phytotherapeutics, and dietary supplements; and designs and markets loungewear made from hemp-derived fabric and materials. The company also manufactures, distributes, and retails cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; lifestyle wellness products, including edibles, bath and body, pets, sports recovery, etc.; provides cannabis consumption accessories, personal storage, and travel accessories for vape and dry herb categories; and offers juices, exotic fruits coated with chocolate, and chocolate bars, as well as dried fruits, beans, and pulp from Amazonian fruits in supermarkets, discount retailers, coffee shops, restaurants, and airports. In addition, it engages in the manufacturing, promotion, and distribution of beverage products; manufacture and sale of product formulations for pain relief; and development of pharmaceutical cannabinoid formula for the prevention of Sars-Cov-2. The company sells its products under the JustCBD, Vessel, Mind Naturals, Mambe, Stardog, Tonino Lamborghini, and Kalaya brands. Flora Growth Corp. was incorporated in 2019 and is headquartered in Toronto, Canada.
How the Company Makes MoneyFlora Growth makes money through several key revenue streams. The primary source of revenue comes from the cultivation and sale of cannabis products, which includes dried flower, oils, and other derivatives. Additionally, the company generates income from its wellness and cosmetics brands, which utilize cannabis-derived ingredients. Flora Growth's revenue model is supported by strategic partnerships and distribution agreements that enable the company to expand its market reach both domestically and internationally. These partnerships often involve collaborations with other companies in the pharmaceutical, cosmetics, and consumer goods industries, enhancing product accessibility and brand recognition. The company's vertically integrated operations, from cultivation to distribution, allow it to maintain cost efficiencies and maximize profitability.

Flora Growth Earnings Call Summary

Earnings Call Date:May 13, 2025
(Q3-2024)
|
% Change Since: -9.59%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant strategic expansions and leadership changes that position Flora Growth for future growth in both the U.S. and European markets. However, the company faced challenges with declining revenue and increased operating expenses. Despite these challenges, the substantial reduction in net loss and strong performance of key brands suggest a cautiously optimistic outlook.
Q3-2024 Updates
Positive Updates
Strategic Expansion in the U.S. and Germany
Flora Growth is leveraging its brands, JustCBD and Vessel, to capture market share in the U.S. with a focus on the growing infused beverage market. In Germany, the company is launching a Parallel Import business to meet the demand for affordable pharmaceuticals.
Significant Reduction in Net Loss
The net loss for the period was reduced to $9.8 million from $47.3 million, an improvement of $37.5 million or 79%.
Strong Performance of JustCBD and Vessel
JustCBD maintained a gross profit margin of 40% with $4.2 million in sales, while Vessel maintained a gross profit margin of 55% with $1.1 million in sales. Both brands continued to expand their wholesale customer base.
New Leadership in European Operations
Dr. Manfred Ziegler, former Managing Director of CC Pharma, was appointed to lead operations in Europe, bringing extensive experience and a successful track record.
Potential Policy Advancements in the U.S.
Positive signals from U.S. political leaders regarding cannabis regulation and the introduction of the Cannabinoid Safety and Regulations Act could benefit Flora's operations.
Negative Updates
Decline in Revenue
Revenues for Q3 2024 were $12.5 million, down from $17.3 million in Q3 2023. Revenue for the first nine months of 2024 was $46.2 million, compared to $58.1 million for the same period in 2023.
Increased Operating Expenses
Total operating expenses increased to $6.5 million in Q3 2024 from $5.5 million in Q3 2023.
Challenges in the German Market
The company experienced softness in its existing German business due to increased competition and the need for business model adjustments.
Company Guidance
During the Flora Growth Corporation Q3 2024 earnings call, the company provided guidance reflecting strategic initiatives and financial metrics. Flora's revenues for the third quarter of 2024 were $12.5 million, down from $17.3 million in the same quarter of 2023, primarily due to discontinuing unprofitable lines. The company reported a net loss of $9.8 million, a significant improvement from the $47.3 million loss in the prior year. Total operating expenses increased to $6.5 million compared to $5.5 million in Q3 2023. JustCBD maintained a gross profit margin of 40% on $4.2 million in sales, while Vessel achieved a 55% margin on $1.1 million in sales. Parallel Import business and regulatory advancements in the U.S. and Germany are seen as key drivers for future growth. The company ended the quarter with $4.2 million in cash and $21.3 million in current assets, including $7.9 million in saleable inventory. Flora is optimistic about leveraging federal rescheduling in the U.S. and regulatory developments in Germany to enhance market presence.

Flora Growth Financial Statement Overview

Summary
Flora Growth's financial performance is under significant pressure. The company is experiencing declining revenue, persistent operating losses, and a deteriorating balance sheet with increased leverage and reduced equity. Although there is slight improvement in free cash flow, overall financial stability remains weak, necessitating strategic interventions to regain profitability.
Income Statement
35
Negative
Flora Growth's income statement shows a significant decline in revenue from $76.07 million in 2023 to $59.51 million in 2024, indicating a negative revenue growth rate of -21.75%. Additionally, the company has been consistently operating at a loss with a negative net profit margin, as net income remains negative across the years, reaching -$15.91 million in 2024. Gross profit margin has also declined from 23.32% in 2023 to 21.00% in 2024, reflecting reduced operational efficiency. These factors point to struggles in maintaining profitability and revenue growth.
Balance Sheet
40
Negative
The balance sheet of Flora Growth highlights a challenging financial position, with a debt-to-equity ratio that has risen to 1.09 in 2024, reflecting increased leverage. Stockholders' equity has decreased significantly, from $6.40 million in 2023 to $4.51 million in 2024. The equity ratio has also declined to 17.20% in 2024, suggesting a lower proportion of equity financing. The company faces potential risks due to its high leverage and declining equity position.
Cash Flow
45
Neutral
Cash flow analysis for Flora Growth reveals some improvement in free cash flow, which, while still negative at -$5.17 million in 2024, has improved from -$8.56 million in 2023. However, operating cash flow remains negative, indicating continuous cash outflows from core operations. The operating cash flow to net income ratio remains unfavorable, given the negative net income. Despite the improvement in free cash flow, the company faces challenges in generating positive cash flow from operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue53.26M59.51M76.07M37.17M8.98M106.00K
Gross Profit11.53M12.50M17.74M14.41M2.42M71.00K
EBITDA-12.83M-15.10M-45.87M-17.91M-20.61M-14.19M
Net Income-13.29M-15.91M-57.04M-52.63M-21.36M-14.26M
Balance Sheet
Total Assets22.39M26.23M23.63M80.99M85.48M19.45M
Cash, Cash Equivalents and Short-Term Investments3.68M6.02M4.35M9.54M37.61M15.52M
Total Debt5.25M4.90M3.67M4.14M1.34M649.00K
Total Liabilities17.64M21.72M17.22M24.57M8.54M3.20M
Stockholders Equity4.76M4.51M6.40M56.82M77.17M16.36M
Cash Flow
Free Cash Flow-6.49M-5.17M-8.56M-17.23M-24.63M-8.65M
Operating Cash Flow-6.42M-5.03M-8.40M-15.94M-20.65M-8.42M
Investing Cash Flow728.00K203.00K-234.00K-15.80M-14.55M-2.16M
Financing Cash Flow5.31M6.49M3.15M4.41M58.11M25.82M

Flora Growth Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.66
Price Trends
50DMA
0.64
Positive
100DMA
0.67
Negative
200DMA
1.00
Negative
Market Momentum
MACD
<0.01
Positive
RSI
47.47
Neutral
STOCH
23.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FLGC, the sentiment is Negative. The current price of 0.66 is below the 20-day moving average (MA) of 0.68, above the 50-day MA of 0.64, and below the 200-day MA of 1.00, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 47.47 is Neutral, neither overbought nor oversold. The STOCH value of 23.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FLGC.

Flora Growth Risk Analysis

Flora Growth disclosed 60 risk factors in its most recent earnings report. Flora Growth reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Flora Growth Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$313.93M-9.20%-3.02%26.00%
51
Neutral
$7.39B0.31-61.07%2.34%17.46%1.71%
44
Neutral
$403.85M-31.06%11.22%-108.58%
42
Neutral
$15.01M-336.65%-28.78%86.97%
40
Underperform
$7.75M-8.46%-9.22%89.90%
39
Underperform
$19.91M-201.88%
31
Underperform
$30.33M-576.46%38.50%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FLGC
Flora Growth
0.66
-0.30
-31.25%
KALA
Kala Pharmaceuticals
4.70
-1.75
-27.13%
YCBD
cbdMD
0.87
-3.75
-81.17%
TLRY
Tilray
0.39
-1.34
-77.46%
SNDL
SNDL
1.22
-0.70
-36.46%
IXHL
Incannex Healthcare Limited Sponsored ADR
0.21
-2.45
-92.11%

Flora Growth Corporate Events

Private Placements and FinancingBusiness Operations and StrategyRegulatory Filings and Compliance
Flora Growth Ends Agreement with Aegis Capital
Neutral
Dec 12, 2024

Flora Growth Corp. and Aegis Capital Corp. have jointly decided to terminate their At-The-Market Issuances Sales Agreement, effective December 12, 2024. Subsequently, Flora Growth filed a prospectus supplement to de-register the common shares previously registered for issuance under this agreement, indicating a shift in their capital raising strategy.

Executive/Board Changes
Flora Growth Restructures Board with New Appointments
Positive
Dec 11, 2024

Flora Growth Corp. announced the resignation of Brendan Cahill from its board of directors and the appointment of Sammy Dorf and Manfred Leventhal as new directors. Sammy Dorf, a notable figure in the cannabis industry, has been appointed as Executive Chairman, bringing significant expertise and potential growth opportunities to Flora Growth. Manfred Leventhal’s appointment as an independent director strengthens Flora’s compliance with Nasdaq’s audit committee requirements and enhances its corporate governance.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 21, 2025